Biotech company Alnylam Pharmaceuticals conceded defeat for now in a lawsuit against Pfizer and BioNTech over technology in ...

The European Court of Justice Wednesday ruled there was no plausible reason to block the New York Times from getting European ...

A top European court says the European Commission failed to provide a credible explanation for refusing The New York Times ...

China said on Wednesday it would further enhance capital market support for science and technology innovation enterprises and ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

Drugmakers' shares fell globally after President Trump said he would [sign an executive order]( ...

Patients taking tofacitinib (Xeljanz) in the drug's late-stage and post-marketing studies were more likely than those on ...

Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...

Vaccines using mRNA are currently being studied for a wide range of diseases, including cancer, cardiovascular disease, ...

Income investors have liked Pfizer (NYSE: PFE) for years. However, the big drugmaker's exceptionally juicy dividend these ...

Investing.com -- Moody’s Ratings has assigned an A2 rating to Pfizer Netherlands International Finance B.V. (PNIF BV), a ...

Evaluate AbbVie Inc. vs. Pfizer Inc. amidst tariff disputes and drug pricing policies. Click for our comparison of ABBV and ...